Related Experiment Video
Updated: Jul 1, 2025

06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
9.8K
Imetelstat: Finally a disease-modifying treatment for lower-risk myelodysplastic syndromes?
Fatemeh Majidi1, Norbert Gattermann1
1Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany.
Med (New York, N.Y.)
|March 9, 2024
Abstract:
Favorable results were achieved in a phase 3 clinical trial (IMerge) with the telomerase inhibitor imetelstat in transfusion-dependent patients with lower-risk myelodysplastic syndromes (MDSs) who relapsed or were refractory to erythropoiesis-stimulating agents.1 Imetelstat is likely to become a useful addition to our limited therapeutic options for patients with MDS.

